

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Toshiyoshi Fujiwara *et al.*

Application No.: 10/520,901

Confirmation No.: 2780

Filed: April 13, 2005

Art Unit: 1652

Title: ONCOLYTIC VIRUS REPLICATING
SELECTIVELY IN TUMOR CELLS

Examiner: W.C. Winston Shen

MAIL STOP AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 C.F.R. § 1.116
IN RESPONSE TO FINAL OFFICE ACTION

In response to the final Office Action mailed by the United States Patent and Trademark Office (the "PTO") on January 20, 2010 in connection with this application and pursuant to Rule 116 of the Rules of Practice, please enter the following amendments and consider the accompanying Remarks. It is believed that no Extensions of Time are required and that no fees are due for this Response. However, should the PTO determine that any Extension(s) of Time is/are required, then Applicants respectfully request that this paper also be considered as a Petition for the required Extension(s) of Time, and that the required Extension(s) be granted. Should the PTO determine that any fee is due or that a refund is owed for this application, then the Commissioner is hereby requested and authorized to charge any required fee(s) (including any required Extension of Time fees) and/or credit any refund(s) owed to Deposit Account No. 06-1050 of Applicants' undersigned representatives.

Amendments to the Claims are shown in the Claim Listing beginning on page 3 of this paper. The claim listing provides a complete listing of all the claims ever presented in this application, with markings to indicate Applicants' proposed amendments, and replaces all prior versions and listings of claims in this application.

Applicant : Toshiyoshi Fujiwara *et al.*
Serial No. : 10/520,901
Filed : April 13, 2005
Page : 2 of 13

Attorney's Docket No.: 27570-0002US1

Amendments to the Drawings are set forth on page 6 of this paper. Replacement and Annotated Sheets of the amended drawings are also attachment to this Response at Exhibit 1.

Remarks/arguments begin on page 7 of this paper.